Morphotek®, Inc. Announces Research Agreement with The University of Pennsylvania to Develop Oncology Therapeutic Antibody Candidates
December 23rd, 2008Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, announced that it has signed a Sponsored Research Agreement with The University of Pennsylvania to fund research for the development of therapeutic antibody candidates targeting an antigen associated with hypoxic regions in tumors. Hypoxia is a condition in which suboptimal oxygen concentrations exist in [...]